Amicus Therapeutics Inc (FOLD)

5.32
0.02 0.37
NASDAQ : Health Care
Prev Close 5.34
Open 5.70
Day Low/High 5.13 / 5.75
52 Wk Low/High 4.98 / 18.83
Volume 5.69M
Avg Volume 3.52M
Exchange NASDAQ
Shares Outstanding 142.69M
Market Cap 759.12M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

October 20th Options Now Available For Amicus Therapeutics (FOLD)

October 20th Options Now Available For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options become available today, for the October 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 276 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Occidental Petroleum and Six Flags Entertainment -- have been scooping up shares of their own stock lately.

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

FOLD Makes Notable Cross Below Critical Moving Average

FOLD Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $7.13, changing hands as low as $6.30 per share. Amicus Therapeutics Inc shares are currently trading off about 22.2% on the day.

Futures Flat as Investors Take Profits; Asia Mixed

Futures Flat as Investors Take Profits; Asia Mixed

Futures remain soft, but analysts believe rally still has steam.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

4 Promising Small Biotechs to Watch in 2017

4 Promising Small Biotechs to Watch in 2017

Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.

First Week of FOLD July 2017 Options Trading

First Week of FOLD July 2017 Options Trading

Investors in Amicus Therapeutics Inc saw new options become available this week, for the July 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Amicus Therapeutics Becomes Oversold (FOLD)

Amicus Therapeutics Becomes Oversold (FOLD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)

First Week of December 16th Options Trading For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options become available this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new December 16th contracts and identified one put and one call contract of particular interest.

Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA

Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA

In trading on Friday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $7.01, changing hands as low as $6.89 per share. Amicus Therapeutics Inc shares are currently trading off about 4.6% on the day.